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Transcatheter aortic valve implantation (TAVI) has achieved
ide spread adoption in many centres worldwide for the treatment
f non-operable and high-risk patients with severe aortic stenosis.
abate et al. present results from a national registry database rep-
esenting 80% of all TAVI cases performed in Spain since January
010, including both available prostheses (Medtronic CoreValve
nd Edwards SAPIEN) and all vascular access routes utilized.1 This
eport provides valuable insight into the overall proﬁle of TAVI
nd treatment of high-risk aortic stenosis patients within a spe-
iﬁc country. Many other published registries provide fragmented
ata with outcomes based upon a speciﬁc device, access route or
elected centres, introducing biases and limiting generalizability of
he data. These results conﬁrm that technical proﬁciency has been
roadly achieved in Spanish TAVI centres with good procedural suc-
ess rates and excellent perioperative outcomes. Their early and
-year results are similar to other published registry data from
anada, United Kingdom, France, Germany, Italy, Belgium and Aus-
ralia/New Zealand,2 which is reassuring for the implanting TAVI
eams as well as their patients.
The authors and all participating TAVI teams in Spain should be
ongratulated on a number of different levels. This report repre-
ents the successful creation of a central National TAVI Committee
o prospectively collect high-quality patient data on TAVI proce-
ures from most of the implanting centres in Spain. This is an
mpressive feat, particularly in the highly politicized climate of
AVI, that demonstrates great collaboration between cardiovas-
ular centres and amongst cardiology and cardiac surgery teams.
hese partnerships are critical for achieving optimal patient out-
omes and for the future of transcatheter valve therapies. This
panish central data repository will serve as an invaluable resource
ot only to monitor trends in TAVI procedures and patient out-
omes but will become a powerful vehicle to develop new science
nd perform multicenter, randomized trials necessary to advance
he ﬁeld of TAVI. Reporting TAVI patient outcomes from a central,
ational registry helps to reduce the impact of the usual biases
nherent to observational case studies, so commonly present within
he TAVI literature. Consideration could be made to expand the
atabase to include all patients with severe aortic stenosis, in par-
icular, medical therapy alone and conventional surgical aortic
alve replacement outcomes, so to provide more comprehensive
ata on the outcomes of the entire disease process itself. If the
emaining Spanish TAVI centres could be convinced to participate
n this initiative as well, it could become a very powerful resource
orldwide for TAVI research.
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Although this report highlights the successful adoption of TAVI
in Spain, it also reinforces the persistent and worrisome com-
plications that occur following TAVI despite improved operator
experience. In-hospital mortality has certainly improved over the
last decade; however, mortality rates appear to have reached a
plateau at about 5% risk in even the most experienced hands. Treat-
ment of extreme risk patients (STS score ≥ 15%) may  be futile, as
patient outcomes have been poor in this population. More impor-
tantly, ongoing 1-, 2- and 3-year mortality rates remain signiﬁcant
despite successful TAVI implantation, suggesting a persistent late
mortality risk, likely related to patient co-morbidities; however,
these could also be related to problems with late stroke and par-
avalvular leak.
Stroke remains a major and devastating complication associ-
ated with TAVI. While some smaller, observational studies report
30-day stroke rates as low as 1.7%, larger, randomized clinical trials
have suggested stroke rates of 6.7% at 30-days and 10.6% at 1 year.3
Although the mechanism of neurologic injury during TAVI is multi-
factorial, manipulation of calciﬁed aortic valves and atheromatous
aortas along with peri-procedural embolic events are likely culprits
in many patients. Recognition of these embolic events has lead to
the development of “embolic deﬂection devices”. These devices are
placed in the aortic arch and are intended to prevent embolic debris
from entering cerebral circulation; however, many of these devices
remain experimental and are largely unproven.4 Careful guidewire
manipulation and minimizing aortic trauma may help to reduce
stroke risk.
Paravalvular leak and aortic insufﬁciency remain an underap-
preciated but signiﬁcant complication after TAVI. Some degree of
paravalvular leak may  occur in up to 75% of patients after TAVI
and signiﬁcant paravalvular leak in 10–20% of patients. This report
by Sabate et al. conﬁrms the ﬁndings of others that moderate or
severe residual aortic insufﬁciency after TAVI is associated with
signiﬁcantly elevated early and late mortality risks.6,7 In fact, even
mild paravalvular leak is associated with a signiﬁcant risk of late
mortality.3,4 Paravalvular leak is an important complication after
TAVI and is associated with at least a 2-fold increase in early and
late mortality risk.7 It is best to be avoided with appropriate valve
sizing and optimal valve positioning; however, when it occurs,
repeat balloon valvuloplasty, valve in valve and surgical aortic valve
replacement should be considered.
Vascular access complications remain the Achilles heel of the
transfemoral arterial approach for TAVI. Major vascular injury such
as thoracic aortic dissection, access site or access-related vascu-
lar injury, end-organ damage, distal embolization from a vascular
source or left ventricular perforation were reported in up 11%
and 16.9% of patients in the PARTNER trial group A and group
B, respectively.3,5 Minor vascular complications were even more
frequent occurring in approximately one-third of all patients at
1-year after TAVI.3 The persistently high incidence of vascular
ular. Published by Elsevier España, S.L. All rights reserved.
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njuries highlights the necessity for appropriate patient selection
nd utilization of alternative access routes such as transapical,
ranssubclavian and direct aortic approaches in patients with inad-
quate iliofemoral diameters. Newer generation, low-proﬁle valves
ay  also play a role in reducing vascular injuries by allowing for a
ecrease in sheath diameter and safer deployment of the prosthe-
is.
Transcathether aortic valve implantation has revolutionalized
he treatment of high risk patients with aortic stenosis in Spain.
hese patients have been afforded signiﬁcant relief of symptoms
nd greatly improved survival because of the excellent care deliv-
red by the collaborative cardiology and cardiac surgery TAVI
eams. Complications after TAVI persist and must be the focus of
uture investigations to improve overall patient outcomes.
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